ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Nit2/ω-amidase as a potential non-invasive diagnostic marker for moyamoya disease.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMoyamoya (MM) is a progressive arteriopathy of the internal carotid artery and its branches that can lead to stroke and can be treated with surgical revascularization. The enzyme Nit2/ω-amidase (NIT2) is involved in glutaminase II and methionine salvage pathways. Recent studies have shown correlations between these metabolic pathways and MM arteriopathy, specifically increases in L-methionine, NO metabolites, and homocysteine. Here, we present data demonstrating that elevated levels of NIT2 correlate with the presence of MM, suggesting that it may have potential utility as a non-invasive biomarker for this condition.
methodsUrine (n = 58) and blood plasma (n = 29) samples were collected from MM patients (aged 0-19) who were undergoing surgical revascularization and compared to samples collected from age- and sex-matched healthy controls (n = 23). The samples were then analyzed using Olink Explore 3072 proteomic proximity extension assays (PEA) to determine expression levels across ~ 3000 validated protein assays, revealing NIT2 as significantly elevated in MM patients compared to controls. We then conducted a secondary analysis of NIT2 using enzyme-linked immunosorbent assay (ELISA) for independent validation. Results were further analyzed for salient radiographic and clinical features, including Suzuki grade, bilateral vs. unilateral disease, radiographic stroke, and transient ischemic attack (TIA).
resultsANOVA analysis of the MM urine and plasma samples showed a statistically significant increase in Nit2/ω-amidase (NIT2) compared to the control samples, with MM patients exhibiting 1.6-2.3-fold increases in plasma expression (p = 0.04) and 4-11-fold increases in urinary expression (p ≤ 0.001). Higher levels of NIT2 in the urine were associated with moyamoya, bilateral disease, higher grade, stroke, and TIA.
conclusionsNIT2 levels are significantly elevated in MM patients compared to matched controls, and higher levels correlate with measures of more severe disease. These novel data, coupled with the association of this molecule with metabolic pathways impacted by MM, support further investigation into NIT2 as a putative biomarker for MM.
Indexed as
Identifiers
42773232What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.